Navigation Links
Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
Date:11/13/2008

CRANBURY, N.J., Nov. 13 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (Amex: PTN) will announce its first quarter, fiscal year 2009 financial results on Monday, November 17, 2008 before the open of the U.S. financial markets.

The Company will also conduct a conference call and live audio webcast hosted by Palatin's executive management team on November 17, 2008 at which they will discuss the results of operations in greater detail and provide an update on corporate developments.

Schedule for the Financial Results Press Release, Conference Call and Webcast

-- Q1-Fiscal Year 2009 Financial Results

Press Release 11/17/2008 at 7:30 a.m. ET

-- Q1-Fiscal Year 2009 Conference Call - Live 11/17/2008 at 11:00 a.m. ET

Domestic Dial-In Number 1-888-263-2919

International Dial-In Number 1-913-312-0381

Passcode: 7115648

-- Q1-Fiscal Year 2009

Conference Call -- Replay 11/17-11/24/2008

Domestic Dial-In Number 1-888-203-1112

International Dial-In Number 1-719-457-0820

Replay Passcode: 7115648

-- Webcast Live and Replay Access http://www.palatin.com

The webcast and replay can be accessed by logging on to the "Investor/Media Center-Webcasts" section of Palatin's website at http://www.palatin.com.

About Palatin Technologies, Inc.

Palatin Technologies, Inc. is a biopharmaceutical company dedicated to the development of peptide, peptide mimetic and small molecule compounds with a focus on melanocortin and natriuretic peptide receptor systems. The melanocortin system is involved in a large and diverse number of physiologic functions, and therapeutic agents modulating this system may have the potential to treat a variety of conditions and diseases, including sexual dysfunction, obesity and related disorders, ischemia-reperfusion injury, hemorrhagic shock and inflammation-related diseases. The natriuretic peptide receptor system has numerous cardiovascular functions, and therapeutic agents modulating this system may be useful in treatment of heart failure, hypertension and other cardiovascular diseases. Palatin's strategy is to develop products and then form marketing collaborations with industry leaders in order to maximize their commercial potential. For additional information regarding Palatin, please visit Palatin Technologies' website at http://www.palatin.com.


'/>"/>
SOURCE Palatin Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
2. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
3. Palatin Technologies Announces New Strategic Objectives and Reports Third Quarter 2008 Financial Results
4. Palatin Technologies to Report Third Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on May 13th
5. Palatin Technologies, Inc. Reports Positive Results of a Phase I Clinical Study With PL-3994 for the Treatment of Congestive Heart Failure
6. Palatin Technologies to Report Second Quarter, Fiscal Year 2008 Financial Results; Teleconference and Webcast on February 11th
7. Palatin Technologies, Inc. Reports Fiscal Year 2008 First Quarter Results; Teleconference and Webcast to be Held on November 9, 2007
8. Palatin Technologies to Report Fiscal Year 2008 First Quarter Results; Teleconference and Webcast on November 9, 2007
9. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2007 Results; Teleconference and Webcast to be held on September 18, 2007
10. Palatin Technologies Refutes Competitive Technologies Contention of Material Breach
11. Palatin Technologies Announces Reacquisition of Full Rights to Bremelanotide Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the ... commercializing products to treat rare diseases where there is ... be hosting an Investor Webcast Event Friday, December 16, ... innate defense regulators (IDRs) as a new drug class, ... the recently announced and published Phase 2 clinical data ...
(Date:12/8/2016)... , Dec. 8, 2016 Eutilex Co. ... billion KRW (US $18.9M) Series A financing. This financing ... G.N. Tech Venture and SNU Bio Angel. This new ... 30.5 billion KRW (US $27.7M) since its founding in ... to bolster the development and commercialization of its immuno-oncology ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... I/II dose escalation and expansion clinical trial for its lead drug candidate, AC0010, ... purpose of the trial was to determine the safety, antitumor activity, and recommended ...
(Date:12/7/2016)... , Dec. 7, 2016 Neogen Corporation (NASDAQ: ... Dr. Dan Kephart as its chief science ... will assume his responsibilities at Neogen effective Jan. 1. ... director for the agribusiness unit of Thermo Fisher Scientific, ... at Life Technologies. His extensive industry experience also includes ...
Breaking Biology Technology:
(Date:6/27/2016)... 2016 Research and Markets has announced the ... report to their offering. The ... to grow at a CAGR of 12.28% during the period ... an in-depth market analysis with inputs from industry experts. The report ... years. The report also includes a discussion of the key vendors ...
(Date:6/21/2016)... VANCOUVER, British Columbia , June 21, 2016 ... been appointed to the new role of principal ... has been named the director of customer development. ... , NuData,s chief technical officer. The moves reflect ... development teams in response to high customer demand ...
(Date:6/9/2016)... 9, 2016  Perkotek an innovation leader in attendance control systems is proud to ... hours, for employers to make sure the right employees are actually signing in, and ... ... ... ...
Breaking Biology News(10 mins):